Literature DB >> 22346388

Diarrhea recurrence in patients with Clostridium difficile-associated diarrhea: Role of concurrent antibiotics.

M Alfa1, G Harding, A Ronald, R Light, N Macfarlane, N Olson, P Degagne, K Kasdorf, A Simor, K Macdonald, L Louie.   

Abstract

OBJECTIVE: To monitor prospectively patients with Clostridium difficile-associated diarrhea (CAD) in a six hundred bed tertiary care hospital to determine which factors influenced the recurrence of the diarrhea.
DESIGN: A prospective, nonrandomized study. After an initial diagnosis of CAD, patients were interviewed, and each week stool samples and environmental samples were monitored for the presence of toxigenic C difficile for as long as the patients remained in hospital. The relationship of concurrent antibiotics, prolonged fecal excretion of organism or toxin, and environmental contamination was assessed. PATIENTS: Over a two-and-a-half year period, 75 consecutive patients with CAD were selected and those who gave their written informed consent were enrolled. A control group to evaluate environmental contamination consisted of 75 patients with diarrhea not associated with C difficile.
RESULTS: Of the 75 CAD patients, 11 (14.7%) had a recurrence of their diarrhea. Diarrhea recurrence was associated with an increased rate of prolonged excretion of toxigenic organism and/or C difficile toxin(s) (nine of 11 [81.8%] compared with nine of 64 [14.1%]; P≤0.0001; relative risk 14.25; 95% CI 3.383 to 60.023). The risk of diarrhea recurrence was not related to a specific antibiotic but to concurrent therapy. Treatment within 30 days of initial CAD-specific treatment with an antibiotic other than metronidazole or vancomycin occurred significantly more frequently in patients with recurrence of diarrhea compared with those who did not have a recurrence (eight of 11 [72.7%] compared with 22 of 64 [34.4%], P=0.022; relative risk 4; 95% CI 1.153 to 13.881). The environmental contamination rate for toxigenic C difficile in week one in the rooms of patients with diarrhea not caused by C difficile was low (two of 75 [2.6%]) compared with week one data for patients with CAD (14 of 75 [18.7%], P=0.002; relative risk 1.922; 95% CI 1.479 to 2.498). The most frequent site contaminated was the bedpan sprayer (eight of 14 [57.1%]). Pulsed field gel electrophoresis analysis of stool and environmental toxigenic isolates indicated that there was not a single endemic strain of C difficile.
CONCLUSIONS: This study indicates that the recurrence of diarrhea may be related to concurrent 'other' antibiotics. Although data indicated that there was a correlation between diarrhea recurrence and prolonged fecal excretion of toxin, further studies are required to clarify the clinical significance.

Entities:  

Keywords:  Clostridium difficile; Diarrhea; Diarrhea recurrence; Nosocomial infection

Year:  1999        PMID: 22346388      PMCID: PMC3250704          DOI: 10.1155/1999/102891

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  22 in total

1.  Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control.

Authors:  K K Lai; Z S Melvin; M J Menard; H R Kotilainen; S Baker
Journal:  Infect Control Hosp Epidemiol       Date:  1997-09       Impact factor: 3.254

Review 2.  Epidemiologic markers of Clostridium difficile.

Authors:  S Tabaqchali
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

Review 3.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

Review 4.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

5.  Inappropriate testing for diarrheal diseases in the hospital.

Authors:  D L Siegel; P H Edelstein; I Nachamkin
Journal:  JAMA       Date:  1990-02-16       Impact factor: 56.272

6.  Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.

Authors:  J R DiPersio; F J Varga; D L Conwell; J A Kraft; K J Kozak; D H Willis
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

8.  Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile.

Authors:  D M Lyerly; L A Barroso; T D Wilkins; C Depitre; G Corthier
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 9.  Epidemiology of nosocomial Clostridium difficile infection.

Authors:  M H Samore
Journal:  Compr Ther       Date:  1993

10.  Serogroup F strains of Clostridium difficile produce toxin B but not toxin A.

Authors:  C Depitre; M Delmee; V Avesani; R L'Haridon; A Roels; M Popoff; G Corthier
Journal:  J Med Microbiol       Date:  1993-06       Impact factor: 2.472

View more
  3 in total

1.  Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea.

Authors:  Wallace J Wang; Sondra Gray; Cristina Sison; Sushma Arramraju; Bijo K John; Syed A Hussain; Sang H Kim; Preeti Mehta; Moshe Rubin
Journal:  Therap Adv Gastroenterol       Date:  2014-01       Impact factor: 4.409

2.  Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile.

Authors:  Jesus A Romo; Laura Markey; Carol A Kumamoto
Journal:  J Fungi (Basel)       Date:  2020-07-03

3.  Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries.

Authors:  Holly Yu; Nestor Flaster; Adrian Lopez Casanello; Daniel Curcio
Journal:  Braz J Infect Dis       Date:  2020-12-05       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.